CAR-NK Patent Incorporates CLDN18.2 Antibody into GS Cell's Immune Cell Platform
Next-Generation Immunotherapy Technology Targets Solid Tumors Such as Gastric and Pancreatic Cancer

GS Cell announced on March 31 that it has filed a patent related to immune cell therapy targeting solid tumors.

GCell company logo image. GCell

GCell company logo image. GCell

View original image

This patent is for a pipeline developed to target CLDN18.2, based on GS Cell's CAR-NK platform. It is an example of expanding the applicability to the field of solid tumors. CLDN18.2 is a protein expressed in various solid tumors such as gastric cancer, pancreatic cancer, and esophageal cancer, and has recently emerged as a major therapeutic target in the global pharmaceutical and biotech industries.


Unlike CAR-T therapies, which utilize the patient's own cells, CAR-NK therapies use cells from healthy donors. This enables the development of an off-the-shelf treatment that can be mass produced.


The innate immune characteristics of NK cells are expected to offer a high level of safety. From the perspectives of manufacturing and supply, this approach is seen as an alternative that can help reduce treatment costs and improve patient accessibility through greater efficiency.



Seongyong Won, CEO of GS Cell, stated, "This patent represents one of the ongoing achievements in the research and development of solid tumor pipelines based on our CAR-NK platform. Through continued R&D, we will further strengthen our global competitiveness."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing